Literature DB >> 25236528

Is the ABCB1 gene associated with the increased risk of gastric cancer development?--preliminary research.

M Zebrowska1, A Salagacka2, A Jelen2, D Jesionek-Kupnicka3, M Mirowski2, E Balcerczak2.   

Abstract

One of the most common malignant diseases, both worldwide and in Poland, is gastric cancer. The pathogenesis of gastric cancer development is not entirely clear. Next to the environmental risk factors, such as Helicobacter pylori infection or dietary habits, the host genetic factors as predispositions to gastric cancer development are discussed. A transmembrane protein that could be associated with predisposition to cancer development is P-glycoprotein (P-gp). Physiologically, P-gp is present in normal tissue of the gastrointestinal tract, where it plays a protective role by transporting xenobiotics from a cell into extracellular environment. P-gp is encoded by the highly polymorphic ABCB1 gene. The most frequent polymorphisms at positions 1236, 2677, and 3435 may affect both the function and amount of protein, thereby leading to a loss of its physiological function, which could increase the predisposition to development of many diseases, including cancer. In this study, the potential significance of the ABCB1 gene in the development and progression of gastric cancer was evaluated. In 19 tissue samples collected from patients with gastric cancer, the ABCB1 gene polymorphisms were identified at positions 1236 and 2677 by automated sequencing and SNP 3435 by the RFLP method. The relative level of ABCB1 expression was measured in 10 samples of gastric cancer and morphologically normal tissues by real-time PCR. For SNPs at positions 1236, 2677, and 3435, no statistically significant differences in genotype frequencies between gastric cancer patients and healthy individuals were found. However, genotype TT for all studied polymorphisms occurred more frequently in the group of gastric cancer patients (31.6, 26.3, 42.1%, respectively) than in the group of healthy individuals (14.6, 13.5, 21.9%, respectively). The lowest relative expression levels of ABCB1 mRNA were observed for genotypes CC of SNP 1236, CC of SNP 3435, and GG of SNP 2677 (median: 0.215, 0.160, 0.160, respectively). There was a tendency that mutant homozygote TT for SNPs at positions 1236, 2677, and 3435 occurred more frequently in the subgroup of patients with Tis or stage I of TNM classification (SNP 1236 p = 0.0760; SNP 2677 p = 0.0813; SNP 3435 p = 0.0760) than in the subgroup of patients with stage II or III. Also the expression levels were lowest (median 0.740) in the group of patients with the less advanced clinical stage of cancer (Tis or I). Preliminary research showed that the ABCB1 gene polymorphisms at positions 1236, 2677, and 3435 were not related to an increased susceptibility of gastric cancer development. However, they may be associated with the inhibition of gastric cancer progression.
Copyright © 2014 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  ABCB1; Expression; Gastric cancer; Polymorphism

Mesh:

Substances:

Year:  2014        PMID: 25236528     DOI: 10.1016/j.prp.2014.08.003

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  3 in total

1.  Haplotype Analysis of MDR1 and Risk for Cervical Cancer in Northeastern Thailand

Authors:  Sophida Phuthong; Wannapa Settheetham-Ishida; Sitakan Natphopsuk; Dariwan Settheetham; Takafumi Ishida
Journal:  Asian Pac J Cancer Prev       Date:  2017-07-27

2.  Genetic polymorphisms in TNIP1 increase the risk of gastric carcinoma.

Authors:  Zhao Liu; Yuting Shi; Yuyan Na; Qi Zhang; Sizhe Cao; Xianglong Duan; Xiyang Zhang; Hua Yang; Tianbo Jin; Yiming Li
Journal:  Oncotarget       Date:  2016-06-28

3.  Genetic variation in ABCB5 associates with risk of hepatocellular carcinoma.

Authors:  Idy C-Y Leung; Charing C-N Chong; Tan T Cheung; Philip C Yeung; Kelvin K-C Ng; Paul B-S Lai; Stephen L Chan; Anthony W-H Chan; Patrick M-K Tang; Siu T Cheung
Journal:  J Cell Mol Med       Date:  2020-08-11       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.